Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

114.23
-2.9800-2.54%
Volume:5.13M
Turnover:591.89M
Market Cap:142.26B
PE:300.61
High:116.98
Open:116.98
Low:114.00
Close:117.21
Loading ...

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Simply Wall St.
·
15 Feb

US Equity Indexes Rise in Week Amid Tariff Tumult, Hot Inflation, Fed on Pause

MT Newswires Live
·
15 Feb

Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
15 Feb

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
14 Feb

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

Zacks
·
14 Feb

Daiwa Securities Adjusts Price Target on Gilead Sciences to $104 From $90, Keeps Neutral Rating

MT Newswires Live
·
14 Feb

BUZZ-Ideaya Biosciences falls as quarterly loss widens

Reuters
·
13 Feb

IDEAYA Biosciences Launching Gilead Trial Collaboration to Evaluate Trodelvy, IDE397 Combination in Lung Cancer

MT Newswires Live
·
13 Feb

IDEAYA Biosciences Inc: IDEAYA Is Study Sponsor and Gilead Will Provide Supply of Trodelvy to IDEAYA

THOMSON REUTERS
·
13 Feb

IDEAYA Biosciences Inc: IDEAYA and Gilead Retain Commercial Rights to Their Respective Compounds

THOMSON REUTERS
·
13 Feb

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

PR Newswire
·
13 Feb

Gilead upgraded to Buy from Hold at DZ Bank

TIPRANKS
·
13 Feb

South African Markets - Factors to watch on February 13

Reuters
·
13 Feb

Evercore ISI Remains a Buy on Gilead Sciences (GILD)

TIPRANKS
·
13 Feb

Gilead Sciences: Strong Performance and Growth Potential in HIV and Oncology Segments Boost Buy Rating

TIPRANKS
·
13 Feb

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

Benzinga
·
13 Feb